This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pharmacokinetic Evaluation of Moxifloxacin Administered Intravenously and Orally in Healthy Volunteers Who Have Had a Gastric Bypass (DRUG10_MOXI)

This study has been completed.
Information provided by:
University Ghent Identifier:
First received: April 22, 2010
Last updated: April 15, 2011
Last verified: April 2011
Roux-and-Y gastric bypass is one of the most common forms of bariatric surgery; due to a reduction in size of the stomach and intestine, the available surface area for the absorption of oral drugs is strongly decreased. This may lead to a reduced bioavailability resulting in a reduced efficacy of the drug. However, in literature there is no information available about the impact of bariatric surgery on the pharmacokinetics of moxifloxacin. This protocol evaluates the moxifloxacin plasma levels, the variability between subjects and the absolute bioavailability, after oral administration of 400 mg moxifloxacin in healthy volunteers who have had a gastric bypass at least 6 months ago and who now have a stable body weight.

Condition Intervention Phase
Gastric Bypass Body Weight Drug: moxifloxacin per IV Drug: moxifloxacin per os Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pharmacokinetic Evaluation of Moxifloxacin Administered Intravenously and Orally in Healthy Volunteers Who Have Had a Gastric Bypass.

Resource links provided by NLM:

Further study details as provided by University Ghent:

Primary Outcome Measures:
  • To evaluate the pharmacokinetics of 400 mg moxifloxacin per IV compared to 400 mg moxifloxacin per os in patients who had a gastric bypass [ Time Frame: 72 hours ]

Estimated Enrollment: 12
Study Start Date: March 2010
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Moxifloxacin IV Drug: moxifloxacin per IV
intravenous administration of 400 mg moxifloxacin (as a 1h-infusion)
Active Comparator: Moxifloxacin oral Drug: moxifloxacin per os
oral administration of 400 mg moxifloxacin in a single dose


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy volunteers who have had a gastric bypass at least 6 months ago and whose body weight has not changed more than 5% during the last 3 months
  • Age between 18 and 60 years old
  • Able to give informed consent

Exclusion Criteria:

  • Other forms of bariatric surgery (Scopinaro and Mason/Sleeve) before gastric bypass surgery
  • Hypersensitivity to moxifloxacin, other quinolones or to any of the excipients
  • Pregnancy and lactation
  • Creatinine clearance < 80 ml/min
  • Transaminases > 2x the upper limit of normal (AST/ALT)
  • Impaired liver function (Child Pugh C)
  • Fasting glycaemia > 125mg/dl
  • Epilepsy
  • Patients with a history of tendon disease/disorder (especially Achilles tendon rupture) related to quinolone treatment
  • Patients with the following heart disorders:

    • Electrolyte disturbance, particularly an uncorrected hypokalaemia
    • Clinically relevant bradycardia
    • Clinically relevant heart failure with reduced left-ventricular ejection fraction
    • Previous history of symptomatic arrhythmias
  • Congenital or documented acquired QT prolongation or concurrently use of drugs that prolong the QT interval:

    • anti-arrhythmics (Classes IA and III)
    • neuroleptics
    • tricyclic antidepressants
    • antimicrobials (e.g. sparfloxacin, intravenous erythromycin, pentamidine, antimalarials particularly halofantrine)
    • some antihistamines (e.g. terfenadine, astemizole, mizolastine)
    • cisapride, intravenous vincamine, bepridil and diphemanil
  • No normal thyroid function
  • All clinically significant disorders that can interfere with the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01130922

University Hospital Ghent
Ghent, Belgium
Sponsors and Collaborators
University Ghent
Principal Investigator: Jan Van Bocxlaer, PhD University Ghent
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Jan Van Bocxlaer, PhD, University Ghent Identifier: NCT01130922     History of Changes
Other Study ID Numbers: 2010/099
Study First Received: April 22, 2010
Last Updated: April 15, 2011

Keywords provided by University Ghent:
Roux-and-Y gastric bypass surgery
stable body weight

Additional relevant MeSH terms:
Body Weight
Signs and Symptoms
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Nucleic Acid Synthesis Inhibitors processed this record on August 17, 2017